Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309420 | 0.78 | L3MBTL1 (0.40) | L3MBTL1POLBMAPTCCNT1CDK9 | |
| SCHEMBL6309413 | 0.78 | CHRNB2 (0.40) | L3MBTL1MAPTTP53KDM4EUSP2 | |
| SCHEMBL5363670 | 0.77 | POLB (0.43) | POLBMAPTTP53KDM4ELMNA | |
| SCHEMBL5663721 | 0.74 | FDPS (0.39) | L3MBTL1USP2GAAALOX15NPSR1 | |
| SCHEMBL5662451 | 0.73 | L3MBTL1 (0.40) | L3MBTL1MAPTCCNT1CDK9 | |
| SCHEMBL5665366 | 0.73 | L3MBTL1 (0.52) | L3MBTL1POLBMAPTLMNAGAA | |
| SCHEMBL6307857 | 0.72 | ALPL (0.40) | L3MBTL1MAPTKDM4ELMNAGAA | |
| SCHEMBL6305871 | 0.72 | L3MBTL1 (0.38) | L3MBTL1POLBMAPTCCNT1CDK9 | |
| SCHEMBL6307784 | 0.71 | GAA (0.41) | L3MBTL1POLBMAPTBRD4LMNA | |
| SCHEMBL6307208 | 0.71 | KDM4E (0.39) | L3MBTL1POLBCCNT1CDK9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | claimed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | claimed |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | ILEX PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | PHAN HIEU TRUNG (CH) | 2003-06-19 | — | — | US | disclosed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | L3MBTL1 748/4885POLB 807/4885MAPT 3923/4885 |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | L3MBTL1 748/4885POLB 807/4885MAPT 3923/4885 |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | APOB, LDLR, HDLBP | L3MBTL1 1294/4885POLB 1192/4885MAPT 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.